NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Thymosin-α1 for Recurrent Implantation Failure

RecruitingPhase 2, Phase 3

Sponsor: Fakih IVF Fertility Center

Conditions: Recurrent Implantation Faliure

Interventions: Thymosin Alpha1, Placebo Control

Countries: United Arab Emirates

Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 40 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. -Women 18-40 years
2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos
3. \- Normal parental karyotypes
4. \- Normal uterine cavity on imaging
5. \- Negative antiphospholipid panel
6. \- Thyroid and prolactin controlled within local reference standards

Exclusion Criteria:

1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine)
2. \- Active malignancy
3. -Active infection
4. \- Uncontrolled systemic disease
5. \- Current systemic immunosuppression

Locations (1)

Abu Dhabi, United Arab Emirates